• Mouse Neutrophil Cell Isolation Kit Workflow

  2026-09-07

  Build a rapid, column-free workflow for obtaining untouched mouse neutrophils from marrow, blood, or spleen. This guide connects high-purity negative selection with functional assays for neutrophil-targeted nanomedicine, including the CD300LD-directed mRNA platform described in recent hepatocellular carcinoma research.

• RIPA Lysis Buffer (Strong) for MMP8 Studies

  2026-09-07

  Build reproducible lysates for macrophage, enteric neuron, tissue, and exosome-protein studies with a detergent-rich formulation designed for efficient protein recovery. This guide connects the MMP8–TGF-β findings in enteric neuronal injury research to practical Western blot, immunoprecipitation, and pathway-validation workflows.

• Biotin Azide for Fzd5 Lipid-Signaling Workflows

  2026-09-05

  Biotin Azide converts terminal-alkyne-bearing biomolecules into affinity-ready probes for selective capture, detection, and mechanistic studies. This workflow-oriented guide shows how to connect click labeling with the Fzd5–cholesterol–Wnt/β-catenin axis while preserving appropriate controls and experimental boundaries.

• Capsaicin Workflows for TRPV1 and KDM1A Studies

  2026-09-04

  Capsaicin enables parallel investigation of TRPV1 ion channel activation, sensory-neuron excitability, inflammation signaling, and KDM1A/LSD1-dependent cancer biology. This practical workflow covers formulation, assay selection, comparative pain studies, and troubleshooting from cell culture to animal models.

• Adefovir Assays: From HBV Mechanism to OAT1

  2026-09-04

  Adefovir and GS-0393 connect HBV polymerase inhibition with renal OAT1 transport research. This guide presents an assay-centered framework for translating biochemical potency, cellular exposure, and transporter kinetics into reproducible hepatitis B virus research.

• T7 RNA Polymerase for Reliable Cell Assays

  2026-09-03

  This scenario-driven guide explains how T7 RNA Polymerase, SKU K1083, can standardize upstream RNA production for cell viability, proliferation, and cytotoxicity studies. It connects template design, reaction handling, control selection, and biological interpretation while distinguishing product-supported facts from assay-specific recommendations.

• Stattic: Practical STAT3 Inhibitor Workflows

  2026-09-03

  Build more informative STAT3 experiments with Stattic by combining dose-response design, pathway-specific readouts, apoptosis assays, and radiation-response testing. The workflow also translates recent lymphatic endothelial findings into a careful, hypothesis-driven strategy for cancer biology and head and neck squamous cell carcinoma research.

• AZD6482 Workflows for PI3Kβ Research

  2026-09-02

  AZD6482 enables isoform-aware studies of PI3Kβ signaling across platelet, metabolic, and cell-state assays. This practical guide translates its biochemical selectivity into dosing, controls, RNA-foci workflows, and troubleshooting strategies while clearly separating established evidence from exploratory applications.

• HDAC3–NRF2–GPX4 Control of CRC Ferroptosis

  2026-09-02

  A 2025 study identifies HDAC3 as an epigenetic suppressor of ferroptosis in colorectal cancer cells and defines an HDAC3–NRF2–GPX4 signaling axis that supports lipid peroxide defense. Pharmacological inhibition or genetic depletion of HDAC3 increased iron accumulation and lipid peroxidation, while GPX4 rescue experiments established a functional link between this pathway and ferroptotic sensitivity.

• SU5416 in PH Models: Beyond Angiogenesis

  2026-09-01

  SU5416 (Semaxanib) is more than a VEGFR2 pathway tool: in pulmonary hypertension research, its timing and disease context determine how exercise, cardiac, and skeletal-muscle findings should be interpreted. This evidence-based guide translates the Zhang et al. model into practical assay decisions.

• AP1903 and the Next Generation of Precision Switches

  2026-09-01

  AP1903 is a chemically controlled FKBP-binding ligand for activating engineered fusion proteins and studying downstream biology with temporal precision. This thought-leadership analysis connects its use in controlled protein activation, apoptosis pathway research, and conditional cell ablation with lessons from multiplexed SARS-CoV-2 receptor-compatibility mapping—while clearly separating validated evidence from forward-looking assay strategy.

• Measuring Cancer Drug Responses Beyond Viability

  2026-08-31

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. Its framework encourages researchers to pair viability measurements with time-aware, death-specific analyses when interpreting anticancer activity in vitro.

• PPM1D–p38 MAPK Control of AKI Pyroptosis

  2026-08-31

  Wang et al. identify WIP1/PPM1D as a negative regulator of p38 MAPK-dependent renal tubular pyroptosis in sepsis-associated acute kidney injury. By integrating single-cell sequencing, human and mouse tissue analyses, HK2-cell experiments, and pharmacological inhibition with CCT007093, the study connects the PPM1D signaling pathway to inflammatory kidney injury while defining important limits for interpretation.

• BRD4770: Reading G9a Biology in Cancer Assays

  2026-08-30

  BRD4770 is a G9a histone methyltransferase inhibitor for connecting H3K9 methylation with proliferation, senescence, and cell death. This article presents an evidence-aware assay strategy that separates direct product findings from mechanistic insights derived from cancer models.

• M344: Mechanism, Evidence, and Workflow

  2026-08-29

  M344 is a cell-permeable histone deacetylase inhibitor with a reported HDAC IC50 of 100 nM. Its research applications include epigenetic regulation, cell differentiation induction, breast cancer cell proliferation inhibition, neuroblastoma and medulloblastoma research, radiation-response studies, and HIV-1 latency experiments.

8488 records 1/566 page Next 12345 下5页 Last page